For research use only. Not for therapeutic Use.
Potent and selective inhibitor of big MAP kinase 1 (BMK1/ERK5). Note: Free base form of XMD8-92 (Axon 1846) is also available.
Keywords: XMD 8-92 trifluoroacetate | supplier | BMK1/Erk5 inhibitor | XMD8-92 | XMD892 | CAS [2108526-77-6] | [1234480-50-2] | MAPK | ERK | Inhibitor | Enzymes
| Catalog Number | I047550 |
| CAS Number | 2108526-77-6 |
| Molecular Formula | C26H30N6O3.C2HF3O2 |
| Purity | ≥95% |
| IUPAC Name | 2-[2-ethoxy-4-(4-hydroxypiperidin-1-yl)anilino]-5,11-dimethylpyrimido[4,5-b][1,4]benzodiazepin-6-one;2,2,2-trifluoroacetic acid |
| InChI | InChI=1S/C26H30N6O3.C2HF3O2/c1-4-35-23-15-17(32-13-11-18(33)12-14-32)9-10-20(23)28-26-27-16-22-24(29-26)30(2)21-8-6-5-7-19(21)25(34)31(22)3;3-2(4,5)1(6)7/h5-10,15-16,18,33H,4,11-14H2,1-3H3,(H,27,28,29);(H,6,7) |
| SMILES | CCOC1=C(C=CC(=C1)N2CCC(CC2)O)NC3=NC=C4C(=N3)N(C5=CC=CC=C5C(=O)N4C)C.C(=O)(C(F)(F)F)O |
| Reference | Q. Yang et al. Pharmacological Inhibition of BMK1 Suppresses Tumor Growth through Promyelocytic Leukemia Protein. Cancer Cell, 2010, 18(3), 258-267. Q Yang and JD Lee. Targeting the BMK1 MAP Kinase Pathway in Cancer Therapy. Clin. Cancer Res. 2011, 17, 3527-3532. |
